Table 1.
The comparison of clinical parameters in the three groups.
| aABPA (n=64) | b A.f (+) Asthma (n=57) | c A.f (−) Asthma (n=33) | Comparison (p-value) | |||
| a vs. b | a vs. c | b vs. c | ||||
| Age (years) | 45.0 (33.5–52.8) | 33.0 (14.5–52.0) | 38.0 (9.0–61.5) | 0.026 | 0.161 | 0.703 |
| Male/Female | 40/24 | 34/23 | 20/13 | 0.926 | 0.924 | 0.772 |
| BMI (kg/m²) | 20.73 (18.64–24.29) | 21.64 (18.36–24.80) | 20.98 (16.78–25.50) | 0.830 | 0.827 | 0.976 |
| Lung function | ||||||
| FVC (%) | 79.87 ± 16.97 | 83.19 ± 19.07 | 94.73 ± 15.98 | 0.649 | 0.000 | 0.007 |
| FEV1 (%) | 64.35 (46.25–84.32) | 60.20 (41.00–90.50) | 88.90 (76.65–102.20) | 0.919 | 0.000 | 0.001 |
| FEV1/FVC (%) | 78.34 ± 20.76 | 75.46 ± 18.70 | 90.39 ± 11.17 | 0.638 | 0.005 | 0.001 |
| PEF (%) | 64.28 ± 25.39 | 62.65 ± 26.25 | 85.80 ± 19.55 | 0.656 | 0.000 | 0.000 |
| MMEF75/25 (%) | 33.08 (12.80–57.83) | 22.00 (14.50–60.60) | 55.10 (41.36–76.15) | 0.379 | 0.006 | 0.001 |
| MEF50 (%) | 37.05 (15.40–63.25) | 22.30 (15.00–68.20) | 54.41 (44.05–75.05) | 0.258 | 0.009 | 0.000 |
| MEF25 (%) | 29.45 (13.67–54.80) | 24.60 (10.20–53.42) | 48.50 (32.25–69.23) | 0.425 | 0.021 | 0.003 |
| FeNO | 76.00 (52.00–89.50) | 40.00 (32.00–52.00) | 44.00 (23.50–69.00) | 0.000 | 0.001 | 0.782 |
| Venous blood cell analysis | ||||||
| WBC (10^9/L) | 8.00 (6.74–9.86) | 8.52 (6.93–9.90) | 8.50 (6.20–10.02) | 0.882 | 0.979 | 0.745 |
| NEUT% | 58.61 ± 13.30 | 59.40 ± 15.35 | 58.16 ± 14.79 | 0.581 | 0.856 | 0.659 |
| LY% | 22.90 (18.03–35.00) | 28.40 (18.40–34.00) | 27.10 (20.40–41.40) | 0.709 | 0.134 | 0.401 |
| EO% | 10.60 (7.20–12.55) | 4.10 (1.20–7.30) | 4.30 (1.20–7.15) | 0.000 | 0.000 | 0.917 |
| NEUT (10^9/L) | 4.25 (3.35–6.28) | 4.50 (3.30–6.40) | 4.40 (3.60–6.25) | 0.716 | 0.898 | 0.859 |
| LY (10^9/L) | 1.80 (1.48–2.53) | 2.40 (1.50–2.60) | 2.10 (1.55–3.05) | 0.528 | 0.293 | 0.735 |
| EO (10^9/L) | 1.65 (1.09–2.26) | 0.33 (0.10–0.54) | 0.27 (0.09–0.65) | 0.000 | 0.000 | 0.606 |
| Induced sputum cytology classification | ||||||
| SNEUT% | 71.95 ± 20.41 | 60.39 ± 24.92 | 54.24 ± 25.66 | 0.067 | 0.003 | 0.261 |
| SMø% | 5.00 (0.50–20.30) | 9.50 (1.00–25.00) | 16.00 (4.63–44.59) | 0.367 | 0.024 | 0.135 |
| SEO% | 21.15 (7.60–35.75) | 5.55 (2.50–14.50) | 5.85 (2.75–9.50) | 0.000 | 0.000 | 0.681 |
| SLY% | 1.02 (0.50–2.00) | 1.05 (0.50–1.50) | 1.25 (1.00–2.50) | 0.844 | 0.146 | 0.116 |
| Infection index | ||||||
| ESR (mm/h) | 18.00 (8.50–26.25) | 12.00 (7.00–20.00) | 12.00 (10.00–21.50) | 0.320 | 0.473 | 0.623 |
| PCT (positive rate) | 80.95% | 77.14% | 75.76% | 0.682 | 0.586 | 0.893 |
ABPA, allergic bronchopulmonary aspergillosis; A.f (+) asthma, Aspergillus fumigatus-sensitized asthma; A.f (−) asthma, non-Aspergillus fumigatus-sensitized asthma; BMI, body mass index; FVC, forced vital capacity; FEV1, forced expiratory volume in 1 s; PEF, peak expiratory flow; MMEF, maximum mid-expiratory flow; MEF50, maximal expiratory flow 50; MEF25, maximal expiratory flow 25; FeNO, fractional exhaled nitric oxide; SNEUT, sputum neutrophils; SMø, sputum macrophages; SEO, sputum eosinophils; SLY, sputum lymphocytes; WBC, white blood cell; NEUT, neutrophils; LY, lymphocytes; EO, eosinophils; ESR, erythrocyte sedimentation rate; PCT, procalcitonin. Bold font indicates statistical significance (p<0.05).